The clinical grade maturation cocktail monophosphoryl lipid A plus IFNγ generates monocyte-derived dendritic cells with the capacity to migrate and induce Th1 polarization

Vaccine

Volumn 25, Issue 41, 2007, Pages 7145-7152

  ten Brinke, Anja ^a   Karsten, Miriam L ^a   Dieker, Miranda C ^a   Zwaginga, Jaap Jan ^a,b   van Ham, S Marieke ^a  

^a SANQUIN RESEARCH   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Dendritic cells; Interferon gamma; Monophosphoryl lipid A

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 12P70; INTERLEUKIN 1BETA; INTERLEUKIN 6; PHOSPHORYL LIPID A; PROSTAGLANDIN E2; SECONDARY LYMPHOID TISSUE CHEMOKINE; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CELL MATURATION; CELL MIGRATION; CELL POLARITY; CELLULAR IMMUNITY; CONTROLLED STUDY; DENDRITIC CELL; GOLD STANDARD; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; PHENOTYPE; PRIORITY JOURNAL; TH1 CELL; TH2 CELL;

CELL PROLIFERATION; CHEMOTAXIS; DENDRITIC CELLS; HUMANS; INTERFERON TYPE II; INTERLEUKIN-12; LEUKOCYTES, MONONUCLEAR; LIPID A; TH1 CELLS;

EID: 34648817211     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.07.031     Document Type: Article

References (25)

1. Figdor C.G., de Vries I.J., Lesterhuis W.J., and Melief C.J. Dendritic cell immunotherapy: mapping the way. Nat Med 10 5 (2004) 475-480
2. Schuler G., Schuler-Thurner B., and Steinman R.M. The use of dendritic cells in cancer immunotherapy. Curr Opin Immunol 15 2 (2003) 138-147
3. Banchereau J., and Palucka A.K. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 5 4 (2005) 296-306
4. Alder J., Hahn-Zoric M., Andersson B.A., and Karlsson-Parra A. Interferon-gamma dose-dependently inhibits prostaglandin E(2)-mediated dendritic-cell-migration towards secondary lymphoid organ chemokines. Vaccine 24 (2006) 7087-7094
5. Mailliard R.B., Wankowicz-Kalinska A., Cai Q., Wesa A., Hilkens C.M., Kapsenberg M.L., et al. Alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Res 64 17 (2004) 5934-5937
6. Sakakibara M., Kanto T., Inoue M., Kaimori A., Yakushijin T., Miyatake H., et al. Quick generation of fully mature dendritic cells from monocytes with OK432, low-dose prostanoid, and interferon-alpha as potent immune enhancers. J Immunother 29 1 (2006) 67-77
7. Jonuleit H., Kuhn U., Muller G., Steinbrink K., Paragnik L., Schmitt E., et al. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol 27 12 (1997) 3135-3142
8. Boccaccio C., Jacod S., Kaiser A., Boyer A., Abastado J.P., and Nardin A. Identification of a clinical-grade maturation factor for dendritic cells. J Immunother 25 1 (2002) 88-96
9. Kalinski P., Vieira P.L., Schuitemaker J.H., de Jong E.C., and Kapsenberg M.L. Prostaglandin E(2) is a selective inducer of interleukin-12 p40 (IL-12p40) production and an inhibitor of bioactive IL-12p70 heterodimer. Blood 97 11 (2001) 3466-3469
10. Kubo S., Takahashi H.K., Takei M., Iwagaki H., Yoshino T., Tanaka N., et al. E-prostanoid (EP)2/EP4 receptor-dependent maturation of human monocyte-derived dendritic cells and induction of helper T2 polarization. J Pharmacol Exp Ther 309 3 (2004) 1213-1220
11. de Vries I.J., Lesterhuis W.J., Scharenborg N.M., Engelen L.P., Ruiter D.J., Gerritsen M.J., et al. Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin Cancer Res 9 14 (2003) 5091-5100
12. Vilella R., Benitez D., Mila J., Lozano M., Vilana R., Pomes J., et al. Pilot study of treatment of biochemotherapy-refractory stage IV melanoma patients with autologous dendritic cells pulsed with a heterologous melanoma cell line lysate. Cancer Immunol Immunother 53 7 (2004) 651-658
13. Scandella E., Men Y., Gillessen S., Forster R., and Groettrup M. Prostaglandin E2 is a key factor for CCR7 surface expression and migration of monocyte-derived dendritic cells. Blood 100 4 (2002) 1354-1361
14. Luft T., Maraskovsky E., Schnurr M., Knebel K., Kirsch M., Gorner M., et al. Tuning the volume of the immune response: strength and persistence of stimulation determine migration and cytokine secretion of dendritic cells. Blood 104 4 (2004) 1066-1074
15. Peng J.C., Thomas R., and Nielsen L.K. Generation and maturation of dendritic cells for clinical application under serum-free conditions. J Immunother 28 6 (2005) 599-609
16. Quillien V., Moisan A., Carsin A., Lesimple T., Lefeuvre C., Adamski H., et al. Biodistribution of radiolabelled human dendritic cells injected by various routes. Eur J Nucl Med Mol Imaging 32 7 (2005) 731-741
17. Ulrich J.T., and Myers K.R. Monophosphoryl lipid A as an adjuvant. Past experiences and new directions. Pharm Biotechnol 6 (1995) 495-524
18. Thoelen S., Van Damme P., Mathei C., Leroux-Roels G., Desombere I., Safary A., et al. Safety and immunogenicity of a hepatitis B vaccine formulated with a novel adjuvant system. Vaccine 16 7 (1998) 708-714
19. McCormack P.L., and Wagstaff A.J. Ultra-short-course seasonal allergy vaccine (Pollinex Quattro). Drugs 66 7 (2006) 931-938
20. Veran J., Mohty M., Gaugler B., Chiavaroli C., and Olive D. OM-197-MP-AC adjuvant properties: the in vitro maturation of normal and leukemic dendritic cells in a serum-free culture model. Immunobiology 209 1/2 (2004) 67-77
21. Ismaili J., Rennesson J., Aksoy E., Vekemans J., Vincart B., Amraoui Z., et al. Monophosphoryl lipid A activates both human dendritic cells and T cells. J Immunol 168 2 (2002) 926-932
22. Vieira P.L., de Jong E.C., Wierenga E.A., Kapsenberg M.L., and Kalinski P. Development of Th1-inducing capacity in myeloid dendritic cells requires environmental instruction. J Immunol 164 9 (2000) 4507-4512
23. Jongmans W., Tiemessen D.M., van Vlodrop I.J., Mulders P.F., and Oosterwijk E. Th1-polarizing capacity of clinical-grade dendritic cells is triggered by Ribomunyl but is compromised by PGE2: the importance of maturation cocktails. J Immunother 28 5 (2005) 480-487
24. Lee A.W., Truong T., Bickham K., Fonteneau J.F., Larsson M., Da S.I., et al. A clinical grade cocktail of cytokines and PGE2 results in uniform maturation of human monocyte-derived dendritic cells: implications for immunotherapy. Vaccine 20 Suppl. 4 (2002) A8-A22
25. Snijders A., Kalinski P., Hilkens C.M., and Kapsenberg M.L. High-level IL-12 production by human dendritic cells requires two signals. Int Immunol 10 11 (1998) 1593-1598